Stay updated on Pembrolizumab Combo vs Placebo in Gastric Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo vs Placebo in Gastric Cancer Clinical Trial page.

Latest updates to the Pembrolizumab Combo vs Placebo in Gastric Cancer Clinical Trial page
- CheckyesterdayChange DetectedThe footer revision identifier changed from v3.7.0 to v3.7.1 while the page continued to display a 403 Forbidden error.SummaryDifference0.2%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page now shows a new Revision: v3.7.0, and sponsor-related footer content and external links (e.g., Merck-specific text and related documents) were removed, altering the footer but not the study details.SummaryDifference20%

- Check43 days agoChange DetectedA funding line for 2023 NIH grant/contract was added to the study page, and the revision history shows the page updated to version v3.6.6, replacing v3.6.5.SummaryDifference0.0%

- Check57 days agoChange DetectedPlain Language Summary text was removed from the Study Details page, eliminating the layperson-friendly overview of the trial's purpose and design. The remainder of the study details remains available.SummaryDifference0.0%

- Check64 days agoChange DetectedThe page revision was updated from v3.6.4 to v3.6.5, indicating a newer version of the study page content. This likely reflects small updates or fixes applied by the publisher.SummaryDifference0.0%

- Check79 days agoChange DetectedRevision label updated from v3.6.3 to v3.6.4, indicating a small update to the page’s version. It does not change any study content or results.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab Combo vs Placebo in Gastric Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo vs Placebo in Gastric Cancer Clinical Trial page.